In our clinical study in psoriasis patients, the cells with TRM markers were increased in the active skin lesion and decreased after the systemic treatment with anti-IL-17A mAb, although they were relatively resistance to the treatment compared to the non-TRM cells (142). The gene discussed is IL17A; the disease is psoriasis.